Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
78882.630.8292%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

LENZ Therapeutics Inc

LENZNASDAQ
Trade with Public
Trade with Public
$5.11
0.306.24%
At close: Aug 28, 5:00 PM EST
$4.72
-0.39-7.59%
After Hours: Aug 28, 5:57 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipDividendsCompareOptionsStock Report

LENZ Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for LENZ Therapeutics (LENZ).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

6Buy
1Hold
Consensus RatingBuy# Analysts7Avg. Consensus PT$30Upside to Avg. PT+541.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026Piper SandlerBiren AminPT CutNeutral$12→$7
Jul 7, 2026HC Wainwright & Co.Matthew CaufieldMaintainedBuy$38
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Buy and maintains $38 price target.
Benzinga Newsdesk

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analysts remain focused on U.S. growth.
Vandana Singh

PRO
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $26 to $20.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $48 to $38.
Benzinga Newsdesk

PRO
Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12

Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Neutral and lowers the price target from $39 to $12.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved